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Abstract
Summary Kinsenoside is able to improve bone turnover rate
in ovariectomized (OVX) mice. In vitro analysis shows that
kinsenoside antagonizes osteoclast development and bone
resorption.
Introduction Kinsenoside, the main active compound of the
traditional Taiwanese herb Anoectochilus formosanus, has
an antiinflammatory effect. This study investigates whether
kinsenoside inhibits osteoporosis and osteoclastogenesis.
Methods OVX mice were used to examine the antiosteopor-
otic activity of kinsenoside. The trabecular bone microarchi-
tecture was assessed by microcomputed tomography. In vitro
experiments were performed to determine the mechanisms of
the antiosteoporotic effects of kinsenoside.
Results Microcomputed tomography scanning showed that
kinsenoside suppresses bone loss in OVX mice. Kinsenoside
decreases plasma CTx concentration. Reverse transcription
polymerase chain reaction (RT-PCR) analysis also showed
that kinsenoside reduces the femoral mRNA expression of
tartrate-resistant acid phosphatase (TRAP) and matrix
metalloproteinase-9 (MMP-9). Kinsenoside inhibits osteoclast
formation in bone marrow cells (BMs) and RAW 264.7 cells.
Western blot was used to analyze osteoclast-associated signaling
pathways in RAW 264.7 cells. Results show that kinsenoside
does not inhibit IKK phosphorylation but suppresses the phos-
phorylation of IκBα and p65. Kinsenoside significantly inhibits
the RANKL induction of IKK activity. Kinsenoside inhibits the
RANKL-triggered nuclear translocations of NF-κB and nuclear
factor of activated T cells c1 (NFATc1). RT-PCR was used to
analyze osteoclast precursor fusion and resorption-associated
gene expression in BMs. Kinsenoside inhibits the expression
of cathepsin K (CAK), dendritic cell-specific transmembrane
protein, MMP-9, and TRAP.
Conclusions Kinsenoside inhibits osteoclastogenesis frommac-
rophages by attenuating RANKL-induced NF-κB and NFATc1
activities, which in turn, prevents bone loss from OVX mice.
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Introduction
Bone remodeling depends on the balance between bone resorp-
tion and bone formation [1]. Postmenopausal osteoporosis
reflects an imbalance in bone remodeling in which osteoclastic
bone resorption exceeds osteoblastic bone formation [2]. The
ovariectomized (OVX)model has been used as an animalmodel
for various clinical syndromes derived from osteoporosis [3].
The serum concentration of C-terminal telopeptides of type I
collagen (CTx) and the serum activity of alkaline phosphatase
(ALP) are markers of bone resorption and bone formation,
respectively [4]. Previous research has shown that CTx and
ALP are significantly greater in an OVX group than in a
sham-operated group [4].
Osteoclasts are bone-resorbing cells derived from hemato-
poietic precursors in the presence of the macrophage colony-
stimulating factor (M-CSF) and the receptor activator of the
nuclear factor-κB ligand (RANKL) [5]. The binding of
RANKL to its receptor RANK leads to the recruitment of
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TNF receptor-associated factor 6 (TRAF6) to the cytoplasmic
domain of RANK [6, 7]. The downstream targets of TRAF6
are predominantly mediated by a trimeric complex containing
the NF-κB essential modulator (NEMO), an inhibitor of NF-
κB kinase (IKK) α and IKKβ. IKK regulates the degradation
of the inhibitor of NF-κB, IκBα, by promoting its phosphor-
ylation and further degradation via the proteasome–ubiquitin
pathway. Liberated NF-κB subsequently translocates into the
nucleus, where it binds to DNA and promotes the transcription
of various genes [8]. NF-κB is important for the initial induc-
tion of the nuclear factor of activated T cell c1 (NFATc1)
expression. NFATc1 binds to its own promoter, thus switching
on a robust induction of NFATc1 [8]. NFATc1 is likely a key
regulator of RANKL-induced osteoclast differentiation,
fusion, and activation [9, 10].
Alendronate is a synthetic agent that is currently the most
widely used drug for postmenopausal osteoporosis. Alendro-
nate is a bone resorption inhibitor that maintains bonemass by
inhibiting the function of osteoclasts [11]. Some people taking
alendronate have experienced severe effects, such as osteo-
necrosis and insufficiency fractures [12, 13]. Growing evi-
dence shows that the benefits of natural products, which are
thought to be healthier and safer for the treatment of osteopo-
rosis, can overcome the side effects of this synthetic drug.
Kinsenoside [3-(R)-3-β-D-glucopyranosyloxybutanolide]
is a significant and active compound of the Anoectochilus
formosanus (Orchidaceae), an important ethnomedicinal plant
in Taiwan [14]. This compound has hepatoprotective, hypo-
glycemic, and antiinflammatory effects [15–17]. Kinsenoside
inhibits NF-κB activation by lipopolysaccharide (LPS) in
mouse peritoneal lavagemacrophages (MPLMs) [17]. Several
reports have shown that crude extracts of A. formosanus can
ameliorate the osteoporosis induced by ovariectomy in rats
[18, 19]. However, the antiosteoporotic activity of kinsenoside
remains unclear.
This study investigates the effects of kinsenoside on
osteopenia in OVX mice, using alendronate as a positive
control drug. In vivo study indicates that the antiosteopor-
otic activity of kinsenoside might be related to its inhibitory
effect on osteoclastogenesis. This study also investigates the
effects of kinsenoside on RANKL-induced NF-κB activation
and on osteoclastogenesis in osteoclast precursor cells.
Materials and methods
Preparation of kinsenoside
Kinsenoside was prepared by Professor Wu. The identity
and purity of kinsenoside (>85 %) were analyzed by HPLC
according to a previous report [15]. For the in vivo study,
kinsenoside was dissolved in distilled water and concentra-
tions of 10 and 30 mg/ml were prepared.
Animals
Female Wistar rats and imprinting control region (ICR) mice
were purchased from BioLASCO Co., Ltd. (Taipei, Taiwan).
The experimental animals received humane care, and the
study protocols complied well with the institutional guidelines
of the China Medical University for the use of laboratory
animals. The animals were housed in an air-conditioned room
(21–24 °C) under 12 h of light (7:00–19:00) and were allowed
free access to food pellets and water throughout the study.
Animal experiments
Female mice were anesthetized with sodium pentobarbital
(40 mg/kg, i.p.) for the bilateral removal of the ovaries. The
mice in the sham-operated group were anesthetized, laparo-
tomized, and sutured without removal of the ovaries. After
3 days of recovery from surgery, the OVX mice were
randomly divided into four groups and orally treated with
vehicle (H2O), kinsenoside (100 and 300 mg/kg daily), or
alendronate (2.5 mg/kg every other day; Sigma-Aldrich, St.
Louis, MO, USA) for 4 weeks. The sham-operated group
was orally treated with H2O only.
Plasma ALP levels were measured using clinical kits
(Roche Diagnostics, Mannheim, Germany) and a spectropho-
tometric system (Cobas Mira; Roche, Rotkreuz, Switzerland).
Plasma CTx levels were determined using a mouse-specific
enzyme-linked immunosorbent assay (ELISA) according to
the manufacturer's protocols (Nordic Bioscience Diagnostics,
Herlev Hovedgade, Denmark).
Microtomography analysis was performed as reported
previously [20]. The trabecular bone microarchitecture of
the distal right femoral metaphysis was measured using
a microtomography scanner (SkyScan 1076, Kontizh,
Belgium), with an isotropic resolution of 18 μm in all three
spatial dimensions. Bone volume and tissue volume were
measured directly from the original three-dimensional
images, and trabecular bone volume (bone volume/tissue
volume, percent) was calculated by dividing the bone
volume by the total volume of interest. Other parameters
of trabecular structure were studied, including thickness,
separation, and the number of trabeculae, as calculated
directly from three-dimensional images.
The left femur was removed, fixed with 4 % neutral-
buffered paraformaldehyde in phosphate-buffered saline
(PBS; pH 7.4) for 48 h, and decalcified in 10 % ethylenedi-
amine tetraacetic acid solution (pH 7.4) at 4 °C for 4 weeks.
After decalcification, each bone sample was cut along the
coronal plane, embedded in paraffin, and cut longitudinally
into sections for histological staining. For measurement of the
osteoclast number, sections were stained for tartrate-resistant
acid phosphatase (TRAP) with TRAP kit (Sigma-Aldrich, St.
Louis, MO, USA) as previously described [21].
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To explore the mechanisms associated with kinsenoside
on OVX-induced osteoporosis in mice, total RNA of the
right tibiae was extracted for analysis of RT-PCR. The
expression levels of ALP, matrix metalloproteinase-9 (MMP-
9), and TRAP were normalized to that of GAPDH mRNA in
the same tissue. The PCR products were separated on a 2 %
agarose gel and recorded on Polaroid film; the band was
quantified with a densitometer. The mean ratio of each group
was calculated as the average for eight animals. The fragments
shown in Fig. 2e reflect the pooled data for eight samples.
Osteoclast differentiation of bone marrow cells
Bone marrow cells (BMs) were prepared by removing bone
marrow from the femora and tibiae of Wistar rats weighing
220–250 g and then flushing the bone marrow cavity with α-
MEM (Hyclone, Logan, UT, USA) supplemented with
20 mM HEPES, 10 % heat-inactivated fetal bovine serum
(FBS), 2 mM glutamine, penicillin (100 U ml−1), and strep-
tomycin (100 μgml−1). The nonadherent cells (hematopoietic
cells) were collected after 24 h and used as osteoclast precur-
sors. Cells were seeded in 1×106 cells/well in 24-well plates
in the presence of RANKL (50 ngml−1; PeproTech EC, Lon-
don, UK) andM-CSF (20 ngml−1; PeproTech EC). Cells were
treated with kinsenoside based on findings that MPLMs do
not undergo any change in viability after exposure to LPS+
kinsenoside. In addition, kinsenoside (IC50, 50 μM) inhibits
the LPS-induced production of IL-1β. Various concentrations
of kinsenoside (10, 25, and 50 μM) were added to these
cultures for 9 days. The culture medium was replaced with
fresh medium every 3 days. Osteoclast formation was mea-
sured using the TRAP staining kit on day 9 [21]. Briefly,
adherent cells were fixed with 10 % formaldehyde in PBS
for 3 min and then stained with naphthol AS-Mx phosphate
and tartrate solution for 1 h at 37 °C. TRAP-positive cells with
more than three nuclei were scored as osteoclasts [22]. The
viability of the BMs was detected by MTS assay (CellTiter 96
AQueous One Solution Cell Proliferation Assay, Promega
Corporation, Madison, WI, USA).
Osteoclast differentiation of RAW 264.7 cells
RAW 264.7 cells, which are derived from murine macro-
phages and obtained from the Food Industry Research and
Development Institute (Hsinchu, Taiwan), were cultured in
dulbecco’s modified eagle medium (DMEM) (Hyclone
Logan, UT, USA) supplemented with 10 % FBS, 100 U/ml
of penicillin, and 100 μg/ml of streptomycin. For differentia-
tion of osteoclasts, RAW 264.7 cells (1×103, in a 24-well
plate) were cultured in the presence of the RANKL (50 ng/ml)
for 5 days. The culture medium was replaced every 3 days.
Various concentrations of kinsenoside (10, 25, and 50 μM)
were added to these cultures. Osteoclast formation was
measured using a TRAP staining kit. The viability of RAW
264.7 cells was also detected by the MTS assay.
Resorption pit assay
RAW264.7 cells were plated on BD BioCoat™ Osteologic™
at a density of 2,000 cells/well in a 96-well tissue culture plate,
and incubated with different concentrations of kinsenoside
(10, 25, and 50 μM) in the presence of RANKL (50 ng/ml)
for 7 days. The culture medium was replaced with fresh
medium containing these stimuli every 3 days. After the
culture, the slices were rinsed with PBS and left overnight in
1 M ammonium hydroxide to remove attached cells. Resorp-
tion pits on BD BioCoat™ Osteologic™ were counted using
the Image Pro-plus program (v. 4.0).
Electrophoretic mobility shift assay
To determine NF-κB activation, the sequencing of the NF-
κB-binding oligonucleotide used a cy5.5-5′-AGCTTGGG-
GACTTTCCGA-3′ DNA probe (Bio-Protech, Taipei, Tai-
wan) as fluorescence. Nuclear protein extracts from RAW
264.7 cells were prepared following the method of Chen et
al. [23]. The DNA binding reaction with nuclear protein was
performed at room temperature in a volume of 20 μl, which
contained the binding buffer (10 mM Tris–HCl, pH 7.5,
50 mM NaCl, 1 mM dithiothreitol (DTT)), 1 μg of poly
(dI-dC), 50 nM cy5.5-labeled probe, 0.5 % Tween 20, and
15 μg of nuclear extracts. After incubation for 30 min, the
samples were electrophoresized on native 5 % acrylamide
gels prepared in a 0.5× TBE buffer (AMRESCO, Solon,
OH, USA). Supershift assays using anti-p65 and anti-p50
antibody were also conducted to confirm the specificity of
NF-κB DNA-binding activity. “Cold” represents a nuclear
extract preincubated with an excess of unlabeled oligonu-
cleotide. The gel was subsequently imaged with a LI-COR
Odyssey Infrared Imaging System (LI COR Biosciences,
Lincoln, NE, USA) in 700-nm channels with a 169 μm
resolution. The density of fluorescence in each band was
measured in triplicate using LI-COR imaging software.
Immunofluorescent staining
Effects of kinsenoside on the nuclear translocation of p65
were examined by immunofluorescence, as described previ-
ously [24]. Briefly, 5×104 RAW 264.7 cells were seeded
onto a 24-well plate preseeded with coverslips. After over-
night incubation to allow for cell attachment, the cells were
preincubated with kinsenoside (10, 25, and 50 μM) for 2 h
before stimulation for 1 h with RANKL (50 ng/ml). After
incubation, cells were washed twice with 1× PBS, fixed for
15 min at room temperature with 4 % paraformaldehyde in
1× PBS (pH 7.4), and then washed extensively with 1×
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PBS. Cells were then permeabilized in 1× PBS containing
0.1 % Triton X-100. After blocking with 0.1 % BSA-PBS,
cells were incubated at 4 °C overnight with anti-p65 antibody
(Cell Signaling, Danvers, MA, USA) diluted 1:200 in PBS.
Cells were then labeled for 1 h at room temperature with an
Alexa Fluor 488 phallotoxin (Molecular Probes, Inc., Eugene,
OR, USA) diluted 1:500 in PBS. Cells were then washed in
PBS as before, counterstained for 3 min at room temperature
with 4'-6-diamidino-2-phenylindole (DAPI) (Santa Cruz
Biotechnology, Inc., CA, USA), and mounted for confocal
microscopy (Leica TCS SP2, Buffalo Grove, IL, USA).
Luciferase assay
To examine NF-κB activation, RAW 264.7 cells (5×104 in
1 ml of fresh medium) were seeded in a 24-well plate before
transfection. The NF-κB luciferase reporter plasmids and
pRL-TK used in this study were obtained from Promega
(Madison, WI, USA). The DNA/jetPEI®-Macrophage mix-
ture was then added to the cells. The cells were incubated in a
humid atmosphere of 5 % CO2 at 37 °C for 6 h. After 6 h, the
transfected cells were treated with kinsenoside for 120 min
and then stimulated with RANKL (50 ng/ml) for 24 h. The
cell lysates were then used for the luciferase assay. Luciferase
activity was measured using a Promega Luciferase Assay
System (Promega). The activity was measured using a Fluo-
roskan® Ascent FL (Thermo Fisher Scientific, Rochester, NY,
USA). The cells were cotransfected with pRL-TK as an inter-
nal control to normalize the reporter gene activity and ensure
the expression of luciferase in all subsequent experiments.
Western blot analysis
RAW 264.7 cells were incubated with or without RANKL in
the presence or absence of kinsenoside. The extraction of
cytoplasmic and nuclear proteins was performed as described
previously [24]. The primary antibodies were obtained from
the following sources: p65, phosphorylated p65 (p-p65),
IκBα, phosphorylated IκBα (p-IκBα), IKKα, IKKβ, and
phosphorylated ΙΚΚα/β (p−ΙΚΚα/β) from Cell Signaling
(Danvers, MA, USA), and proliferating cell nuclear antigen
(PCNA), α-tubulin, p50, and NFATc1 from Santa Cruz (CA,
USA). The whole-protein extracts prepared following the
method described by Lee et al. were used for the Western blot
analysis of NFATc1 expression [25]. Western blot analysis
was performed as described previously [17].
IKK activity assay
IKK activity was measured by an IKKα KinEASE™ FP
Fluorescein Green Assay Kit (Millipore, Billerica, MA,
USA) following the manufacturer's instructions. A fluores-
cence polarization assay was performed using a Synergy 2
fluorescence plate reader (BioTek Instruments, Inc., USA)
with excitation set at 485 nm and emission at 530 nm.
RT-PCR analysis
The BMs were cultured for 3 days in the presence of M-CSF
(20 ng/ml). Adherent cells were used as osteoclast precur-
sors. To generate osteoclasts, osteoclast precursors were
cultured with M-CSF (20 ng/ml) and RANKL (50 ng/ml)
for 3 days in the presence of kinsenoside. Total RNA was
extracted with TRIzol (Invitrogen, Carlsbad, CA, USA)
following the manufacturer's instructions. The PCR primer
sequences for mouse ALP, cathepsin K (CAK), dendritic
cell-specific transmembrane protein (DC-STAMP), MMP-
9, RANK, TRAF6, and TRAP were as follows: primers for
ALP were 5′-GTATGCCTCCTGCATTGGGG-3′ (sense)
and 5′-TGTTCCTGCTGGAAGTTGCC-3′ (antisense); pri-
mers for CAK were 5′-CTGCCCATAACCTGGAGG-3′
(sense) and 5′-GCCCTGGTTCTTGACTGG-3′ (antisense);
primers for DC-STAMP were 5′-ACCCGTTGCCCT
GCTCTCTT-3′ (sense) and 5′-ACGGAGGCCACACGA
CAGAA-3′ (antisense); primers for GAPDH were 5′-
CTTCATTGACCTCAACTACATGGTCTA-3′ (sense) and
5′-GATGACAAGCTTCCCATTCTCAG-3′ (antisense); pri-
mers for MMP-9 were 5′-GGTCTAGGCCCAGAGGTA-3′
(sense) and 5′-GGTCGTAGGTCACGTAGC-3′ (antisense);
primers for RANK were 5′-GTGACTCTCCAGGTCAC
TCC-3′ (sense) and 5′-GGCAGACACACACTGTCG-3′
(antisense); primers for TRAF6 were 5′-GTTCTCAGG
GAGCCCTAC-3′ (sense) and 5′-GAGGCACAGCTAAGG-
GAC-3′ (antisense); primers for TRAP were 5′-GAACCGT
GCAGACGATGG-3 ′ (sense) and 5 ′-GGAAGTTC
CAGCGCTTGG-3′ (antisense). The expected sizes of PCR
products were 232 bp for ALP, 230 bp for CAK,
109 bp for DC-STAMP, 99 bp for GAPDH, 310 bp
for MMP-9, 134 bp for RANK, 364 bp for TRAF6, and
231 bp for TRAP. All primer sets were designed using
NCBI/Primer-BLAST.
Statistical analysis
This study expresses results as the mean ± SD. All experi-
mental data were analyzed by one-way analysis of variance
Fig. 1 Microtomography analysis of metaphysic of the distal femurs
in OVX mice of different groups. a Representative sample from each
group: 3D architecture of trabecular bone within the distal femoral
metaphyseal region. Effects of kinsenoside and alendronate on the
trabecular bone volume (b), thickness of the trabeculae (c), number
of trabeculae (d), and separation of trabeculae (e) of the distal femoral
metaphysic in OVX rats by microtomography analysis. Values are
means ± SD (n08). Values not sharing a common superscript differ
significantly. Ale alendronate, BV/TV bone volume/tissue volume,
Tb.Th thickness of the trabeculae, Tb.N number of trabeculae, Tb.Sp
separation of trabeculae
b
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(ANOVA) following the Duncan's test. A p value <0.05 was
considered statistically significant.
Results
MicroCT analysis in OVX mice
Figure 1a shows 3D renderings of the trabecular bone com-
partment as imaged by micro-computed tomography
(microCT).Microtomography scanning showed that trabecular
bone volume (38 %; p<0.05), trabecular thickness (29 %; p<
0.05), and the number of trabeculae (25 %; p<0.05) in the
distal femoral metaphysis decreased significantly in OVXmice
(Fig. 1b–d). In addition, trabecular separation (42 %; p<0.05)
in the distal femoral metaphysis increased significantly in
OVX mice (Fig. 1e). Treating OVX mice with kinsenoside
led to a 14 % (100 mg/kg; p<0.05) and 23 % increase (300
mg/kg; p<0.05) in trabecular bone volume, a 28 % increase
(300 mg/kg; p<0.05) in trabecular thickness, a 13 %
(100 mg/kg; p<0.05) and 40 % increase (300 mg/kg;
p<0.05) in the number of trabeculae, and an 8 % (100 mg/kg;
p<0.05) and 15 % (300 mg/kg; p<0.05) decrease in trabecular
separation. Treating OVX mice with alendronate produced a
17 % (p<0.05) increase in trabecular bone volume, a 20 %
(p<0.05) increase in the number of trabeculae, and a 24 %
(p<0.05) decrease in trabecular separation.
Biochemical analysis in OVX mice
Four weeks after the operation, the OVX mice showed signif-
icant increases in plasma CTx concentrations (p<0.05) and
ALP activities (p<0.05), compared with the sham-operated
mice (Fig. 2a). Four weeks after kinsenoside administration,
mice in the OVX + vehicle and OVX + kinsenoside groups
showed no differences in the plasma level of ALP. The OVX
mice receiving kinsenoside (100 and 300 mg/kg; p<0.05) and
alendronate (2.5 mg/kg every other day; p<0.05) for 4 weeks
had significantly lowered plasma CTx concentration.
Bone histology analysis in OVX mice
Figure 2c and d show that the number of osteoclasts in the
region of the primary spongiosa significantly increased in the
Fig. 2 Biochemical, histological, and RT-PCR analyses on the
metaphysis of the distal femur or tibiae in OVX mice. a Effects
of kinsenoside on plasma ALP levels in OVX mice. b Effects of
kinsenoside on plasma CTx levels in OVX mice. c Photomicro-
graph of femur section of OVX + H2O group. d Histogram
representing the osteoclast number/mm bone surface (N. Oc/BS).
e Fragments were amplified by RT-PCR. f The expression levels
of ALP, TRAP, and MMP-9 mRNA were measured and quantified
densitometrically. Values were normalized to GAPDH mRNA
expression. All values are means ± SD (n08). Values not sharing
a common superscript differ significantly. c 100×
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OVX mice (p<0.05). Kinsenoside (100 and 300 mg/kg) and
alendronate treatments decreased the number of osteoclasts in
OVX mice (p<0.05).
RT-PCR analysis of tibial mRNA expression in OVX mice
The fragments shown in Fig. 2e reflect the pooled data for
eight samples. The RT-PCR analysis of the tibial sample in
Fig. 2f shows that the expressions of ALP, TRAP, andMMP-
9 were 168 % (p<0.05), 157 % (p<0.05), and 220 % (p<
0.05) higher in the OVX group than in the sham group.
Treatment with kinsenoside led to 23 % (100 mg/kg) and
32 % (300 mg/kg; p<0.05) decreases in TRAP expression
and 27 % (100 mg/kg, p<0.05) and 36 % (300 mg/kg,
p<0.05) decreases in MMP-9 expression. Treatment with
alendronate led to a 54 % (p<0.05) decrease in TRAP
expression and a 41 % (p<0.05) decrease in MMP-9
expression. Kinsenoside and alendronate did not affect
ALP mRNA expression.
Kinsenoside inhibited RANKL-induced osteoclastogenesis
of BMs and RAW 264.7 cells
Treating BMs with kinsenoside (10–50 μM) for 3 days did
not affect cell viability, which was assessed by the MTS
assay (data not shown). Figure 3a shows that kinsenoside
does-dependently inhibited the formation of large TRAP-
positive multinucleated osteoclasts in BM cultures in the
presence of M-CSF and RANKL. Kinsenoside inhibited
osteoclast formation by 17 % (p<0.05), 26 % (p<0.05),
and 50 % (p<0.05) at 10, 25, and 50 μM, respectively.
Treating RAW 264.7 cells with kinsenoside (10–50 μM)
for 3 days did not affect cell viability, which was assessed
by the MTS assay (data not shown). Figure 3b shows that
kinsenoside dose-dependently inhibited RANKL-induced
osteoclast differentiation in RAW 364.7 cells. Kinsenoside
inhibited osteoclast formation by 20 % (p<0.05), 60 %
(p<0.05), and 71 % (p<0.05) at 10, 25, and 50 μM,
respectively.
Kinsenoside inhibited early-stage osteoclastogenesis
Complete osteoclast differentiation of RAW 264.7 cells
takes up to 5 days after RANKL stimulation. To identify
which stage of osteoclastogenesis was affected by kinseno-
side, RAW 264.7 cells were treated with 50 μM of kinseno-
side on different days, from Day 0 to Day 4 after RANKL
stimulation. Kinsenoside inhibited osteoclast formation
by concurrent addition (Day 0) or by Day 1 after
RANKL stimulation (Fig. 3c and d). When kinsenoside
was added to the culture for the final 3 days (Days
2–4), it failed to suppress RANKL-induced osteoclast
differentiation. Kinsenoside inhibited osteoclast formation by
44 % (p<0.05) and 32 % (p<0.05) at Day 0 and Day 1,
respectively.
Kinsenoside inhibited bone resorption
RAW264.7 cells were plated on bone slices and stimulated
with RANKL in the presence or absence of kinsenoside.
RANKL-stimulated cells formed a number of pits (Fig. 3e),
indicating that the bone resorption activity of RANKL-treated
cells transformed them into functionally active state resem-
bling osteoclasts. Treatment with kinsenoside (10–50 μM)
significantly reduced the number and area of resorption pits
compared with RANKL treatment alone. Kinsenoside
inhibited osteoclast resorption by 20 % (10 μM; p<0.05),
34 % (25 μM; p<0.05), and 67 % (50 μM; p<0.05).
Kinsenoside inhibited RANKL-induced NF-κB activation
by electrophoretic mobility shift assay
RAW 264.7 cells were pretreated with kinsenoside for 2 h
and then treated with RANKL for 1 h. The prepared nuclear
extracts were then assayed for NF-κB activation by the
electrophoretic mobility shift assay (EMSA). Figure 4a–c
show that RANKL treatment caused a significant increase in
the DNA-binding activity of NF-κB (p<0.05). Treating
RAW 264.7 cells with kinsenoside (25 and 50 μM)
significantly suppressed the RANKL-induced DNA-binding
activity of NF-κB by 13 % (p<0.05) and 35 % (p<0.05),
respectively.
Kinsenoside inhibited RANKL-induced NF-κB activation
by immunofluorescence staining
Figure 4d shows that, in the absence of RANKL, most p65
were located in the cytoplasm. However, nearly all p65 was
located in the nucleus after RANKL stimulation. The
nuclear translocation of p65 was blocked when incubation
occurred with 25 and 50 μM kinsenoside combined with
RANKL.
Kinsenoside inhibited RANKL-induced NF-κB activation
by luciferase assay
The luciferase reporter gene assay in this study shows the
effects of kinsenoside on NF-κB activity. RAW 264.7 cells
were transiently transfected with an NF-κB-driven luciferase
reporter construct. RANKL induced an increase in NF-κB
promoter-driven luciferase gene expression compared to
RAW 264.7 cells cultured in a medium without RANKL
(Fig. 4e; p<0.05). Treating RAW 264.7 cells with kinsenoside
(10, 25, and 50 μM) strongly inhibited RANKL-induced NF-
κB transcriptional activation by 20 % (p<0.05), 37 % (p<
0.05), and 45 % (p<0.05), respectively.
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Fig. 3 Kinsenoside inhibited RANKL-induced osteoclastogenesis and
bone resorption. a BMs were cultured with the indicated dose of
kinsenoside in the presence of M-CSF and RANKL. After 9 days, cells
were fixed and stained with TRAP. Multinucleated osteoclasts were
counted. b RAW 246.7 cells were cultured with the indicated dose of
kinsenoside in the presence of RANKL. After 5 days, cells were fixed
and stained with TRAP. Multinucleated osteoclasts were counted. c
Kinsenoside inhibited RANKL-induced osteoclastogenesis at an early
stage. The TRAP stains of osteoclasts were treated with kinsenoside
(50 μm) at the same time or after indicated time periods. Cells were
cultured for 5 days after RANKL treatment and stained for TRAP
expression. Multinucleated osteoclasts were counted. The quantitative
data are shown in d. e RAW 246.7 cells plated on BD BioCoat™
Osteologic™ and incubated with different concentrations of kinseno-
side in the presence of RANKL (50 ng/ml) for 7 days. Cells were
removed by washing with distilled water and resorbed areas were
measured. The quantitative data are shown in f. All values are
expressed as means ± SD (n03). Values not sharing a common super-
script differ significantly. c ×100
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Effects of kinsenoside on nuclear translocation of p65
and p50 in RANKL-stimulated RAW 264.7 cells
Treatment with RANKL for 60 min caused the translocation
of p65, but not p50, into the nucleus by Western blot analysis
(p<0.05). The nuclear translocation of the p65 subunit in the
RANKL group was 4.2 times greater than that in the control
group (Fig. 5a). RAW 264.7 cells were incubated with kinse-
noside for 120 min and then treated with RANKL. Kinseno-
side led to a 12 % (25 μM; p<0.05) and 38 % (50 μM; p<
0.05) decrease in p65 expression (Fig. 5a).
Kinsenoside inhibited NFATc1 expression
RAW 264.7 cells were incubated with RANKL in the presence
or absence of kinsenoside for 2 h. Treatment with RANKL for
24 h raised the protein expression levels of NFATc1 byWestern
blot analysis (Fig. 5b; p<0.05). The expression level of
NFATc1 in the RANKL group was 3.5 times greater than that
in control group. Pretreatment with kinsenoside led to a 40 %
(25 μM; p<0.05) and 60 % (50 μM; p<0.05) decrease in
NFATc1 expression (Fig. 5b).
Effects of kinsenoside on cytoplasmic phosphorylation
levels of p-IκBα, p-p65, and p-IKKα/β in RANKL-
stimulated RAW 264.7 cells
RAW 264.7 cells were incubated with RANKL in the pres-
ence or absence of kinsenoside for 2 h. Treatment with
RANKL for 1 h increased the cytoplasmic phosphorylation
levels of p-IκBα, p-p65, and p-IKKα/β, but not IκBα, IKKα,
and IKKβ, by Western blot analysis (Fig. 5c and d). The
Fig. 4 Kinsenoside inhibited RANKL-induced transcriptional activity
of NK-κB in RAW 264.7 cells. a EMSA results showed a supershift of
complex formed in the presence of anti-p50 and anti-p65 antibodies.
The p65 subunits cause a specific binding of NF-κB to consensus DNA
sequence. Cold the nuclear extract was preincubated with an excess of
unlabeled oligonucleotide. b RAW 264.7 cells were incubated with or
without the indicated concentrations of kinsenoside for 2 h and then
treated with RANKL for 1 h and tested for nuclear NF-κB by EMSA.
The quantitative data are shown in c. d RAW 264.7 cells were
pretreated with kinsenoside and then stimulated with RANKL for
1 h. The localization of p65 was visualized by immunofluorescence
analysis. e RAW 264.7 cells were transiently transfected with an NF-
κB promoter plasmid for 16 h. After transfection, the cells were
incubated with the indicated concentrations of kinsenoside for 2 h
and then treated with RANKL for an additional 24 h. Cells were lysed,
and the luciferase activity was determined by using a luciferase report-
er assay system. Values are expressed as means ± SD (n03). Values not
sharing a common superscript differ significantly
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phosphorylation levels of p-IκBα and p-p65 in the RANKL
group were 182 % (p<0.01) and 182 % (p<0.05), respective-
ly, both of which were greater than those in the control group.
Kinsenoside treatment did not affect the level of IκBα. Kin-
senoside treatment led to 27 % (25 μM; p<0.05) and 39 %
(50 μM; p<0.05) decreases in p-IκBα level and 16 %
(10 μM; p<0.05), 32 % (25 μM; p<0.05), and 39 %
(50 μM; p<0.05) decrease in p-p65 level (Fig. 5c).
The levels of p-IKKα/β in the RANKL group were
145 % (p<0.05) greater than that in the control group.
Kinsenoside treatment did not affect the levels of IKKα,
IKKβ, and p-IKKα/β (Fig. 5d).
Kinsenoside inhibited IKK activity
To determine whether kinsenoside interacts with IKK di-
rectly, this study examines the effects of kinsenoside on IKK
enzymatic activity. The culture treatment of RAW 264.7
cells with 50 ng/ml RANKL for 1 h effectively increased
IKK activity. Kinsenoside treatment (10–200 μM) for 2 h
inhibited IKK activity in a concentration-dependent manner.
The IC50 value was approximately 57.6 μM (Fig. 5e).
Kinsenoside did not affect the mRNA expression of RANK
and TRAF6
The fragments shown in Fig. 6a reflect the pooled data for
three samples. The BMs were incubated with M-CSF
Fig. 6 Effects of kinsenoside on expression of RANKL-regulated
genes. a BMs were preincubated for 2 h with indicated concentrations
of kinsenoside and then activated for 24 h with RANKL. RANK and
TRAF6 mRNAs were amplified by RT-PCR. b Total RNA from BMs
was isolated on the indicated days after RANKL incubation, and
mRNA expression of TRAP, DC-STAMP, CAK, and MMP-9 was
analyzed by RT-PCR. c BMs were preincubated for 2 h with indicated
concentrations of kinsenoside and then activated for 24 h with
RANKL. TRAP, DC-STAMP, CAK, and MMP-9 mRNAs were am-
plified by RT-PCR. The quantitative data are shown in d. Values are
mean ± SD (n03). ##p<0.01 as compared with the control group.
Values not sharing a common superscript differ significantly
Fig. 5 Western blot analysis and kinase activity assay of IKKα. a RAW
264.7 cells were preincubated for 2 h with indicated concentrations of
kinsenoside and then activated for 1 h with RANKL. Nuclear fractions
were obtained for the detection of p65 and p50 levels. b RAW 264.7 cells
were preincubated for 2 h with indicated concentrations of kinsenoside
and then activated for 24 h with RANKL. The whole proteins were
obtained for the detection of NFATc1 levels. c Cytoplasmic fractions
were obtained for the detection of p-IκBα, IκBα, and p-p65 levels. d
Cytoplasmic fractions were obtained for the detection of IKKα, IKKβ,
and p-IKKα/β levels. All values are expressed as means ± SD (n03).
Values not sharing a common superscript differ significantly. e In vitro
kinase assay of IKK was done as described in “Materials and methods”.
The IC50 values were approximately 57.6 μM. Values were expressed as
means ± SD (n03)
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(20 ng/ml) for 3 days to induce the production of osteoclast
precursor. Osteoclast precursors incubated with kinsenoside
for 120 min were then treated with M-CSF (20 ng/ml) and
RANKL (50 ng/ml) for 1 day in the presence or absence of
kinsenoside. As Fig. 6a shows, RT-PCR amplified frag-
ments of RANK and TRAF6. The RANK/GAPDH and
TRAF6/GAPDH ratios in the RANKL group were 170 %
(p<0.05) and 220 % (p<0.05), respectively, both of which
are greater than those in the control group. Kinsenoside
treatment (10–50 μM) did not affect the ratios of RANK/
GAPDH and TRAF6/GAPDH (Fig. 6a).
Kinsenoside inhibited the mRNA expression of CAK,
DC-STAMP, MMP-9, and TRAP
The osteoclast fusion and resorption-related gene were activat-
ed lately. To confirm the RANKL-induced expression of these
genes, mRNA was extracted 24, 48, and 72 h after RANKL
challenge for RT-PCR analysis. Figure 6b shows that all TRAP/
GAPDH, DC-STAMP/GAPDH, MMP-9/GAPDH, and CAK/
GAPDH ratios in the 24–72 h after RANKL treatments were
greater than those in the control group. Therefore, mRNA from
BMs challenged with RANKL for 24 h was used to examine
the effects of kinsenoside. Figure 6c and d show that kinseno-
side treatment (10–50 μM) led to 22 % (25 μM; p<0.05) and
48 % (50 μM; p<0.05) decreases in CAK expression, 27 %
(25 μM; p<0.05) and 33% (50 μM; p<0.05) decreases in DC-
STAMP expression, 28 % (25 μM; p<0.05) and 33% (50 μM;
p<0.05) decreases in MMP-9 expression, and 28 % (25 μM;
p<0.05) and 37 % (50 μM; p<0.05) decreases in TRAP
expression.
Discussion
In the present study, kinsenoside ameliorated OVX-induced
osteopenia in mice, through the inhibition of osteoclatogen-
esis. The in vitro study also indicates that kinsenoside inhib-
its osteoclastogenesis from BMs and RAW 264.7 cells.
This study used a mouse model to evaluate the efficacy of
kinsenoside in the treatment of postmenopausal osteoporo-
sis. Microtomographic scanning shows a decrease in trabec-
ular bone volume, thickness, and the number of trabeculae,
with an increase in the trabecular separation of the meta-
physis of the femur in the OVX mice. Treatment with
kinsenoside significantly reduced this bone loss in the
OVX mice.
The plasma activity of ALP, an index of bone formation
[4], was reported to be significantly greater in an OVX
group than in a sham-operated group [4]. A similar change
was observed in the present study. Kinsenoside treatment
did not influence the activity of plasma ALP. CTx is a
marker of bone resorption [4], and OVX increases the
content of CTx in the plasma; however, this effect was
decreased through treatment with kinsenoside. These results
suggest that kinsenoside ameliorated bone loss induced by
OVX by inhibiting bone resorption as opposed to enhancing
bone formation. In the present study, kinsenoside ameliorat-
ed OVX-induced osteopenia in mice through the inhibition
of osteoclatogenesis. The in vitro study also indicates that
kinsenoside inhibits osteoclastogenesis from BMs and RAW
264.7 cells.
Osteoclasts are multinucleated cells of hematopoietic
origin and are the primary bone-resorbing cells [5]. TRAP
is a different form of the enzyme acid phosphatase, which is
found mainly in bone. Osteoclasts release TRAP during
bone resorption [21]. Histological sections stained with
TRAP showed that the number of osteoclasts decreased in
the region of the spongiosa in kinsenoside-treated OVX
mice. TRAP activity is commonly used as a histochemical
marker of identifying osteoclasts [26]. MMP-9 is required
for osteoclastic migration and resorption [27]. Kinsenoside
treatment inhibited the mRNA expression of femoral TRAP
and MMP-9, but not ALP. These findings indicate that
kinsenoside can suppress the differentiation and resorption
of osteoclasts. These results agree with the findings obtained
by Masuda et al., who showed that the ethanolic extract of
A. formosanus inhibited bone loss caused by OVX by sup-
pressing osteoclast formation [18].
Osteoclasts are multinucleated cells originating from the
fusion of mononuclear progenitors in the monocyte/macro-
phage family [28]. Previous research has shown that two
key molecules, M-CSF and RANKL, are essential and suf-
ficient to promote osteoclastogenesis [8]. Thus, M-CSF and
RANKL were added to induce osteoclastogenesis in the
primary BM cell culture system. In the RAW 264.7 macro-
phage cell-cultured system, only RANKL was added to
induce osteoclast differentiation. In this study, kinsenoside
dose-dependently suppressed the formation of osteoclasts in
BMs and a RAW 264.7 cell culture system. Results further
show that RAW 264.7 cells were markedly blocked by the
concurrent administration of RANKL and kinsenoside and
weakly blocked by subsequent addition of kinsenoside. This
suggests that inhibition occurred during the initial stage of
osteoclastogenesis.
Previous research has shown that M-CSF enhances
RANKL-induced osteoclast formation [29]. To exclude the
interference of M-CSF, therefore, RANKL-induced RAW
264.7 cell differentiation into osteoclastlike cells was used
to assess the effects of kinsenoside on the signal transduc-
tion pathway. In addition, a BM system was used to examine
the effects of kinsenoside on osteoclast precursor fusion,
osteoclast formation, and resorption.
Activation of the NF-κB pathway is a key factor in
RANKL-induced osteoclast differentiation [10]. The results
of EMSA analysis show that kinsenoside inhibits the
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RANKL-induced DNA binding activity of p65. Immunoflu-
orescence staining and Western blot analysis of nuclear
protein also show that kinsenoside suppressed the nuclear
translocation of p65 protein. Using transient transfection
with κB-luciferase as an indicator of NF-κB activity, this
study shows that kinsenoside inhibits the RANKL-increased
NF-κB activity. These results clearly show that the antios-
teoclastogenic effects of kinsenoside may occur through the
inhibition of NF-κB signaling.
RANK lacks intrinsic enzymatic activity in its intracellular
domain, and it transduces signaling by recruiting adaptor
molecules such as the TRAF family of proteins [8]. Genetic
experiments show that TRAF6 is required for osteoclast for-
mation and osteoclast activation [30]. The binding of RANKL
to its receptor RANK recruits TRAF6 and subsequently ini-
tiates a kinase cascade. RT-PCR analysis shows that kinseno-
side did not reduce the RANKL-induced mRNA expression
of RANK and TRAF-6, indicating that kinsenoside inhibits
NF-κB activation through downstream kinase to TRAF6.
The classical NF-κB signaling pathway involves the acti-
vation of the IKK complex, which phosphorylates IκBα and
targets them for ubiquitin-dependent degradation [8]. In the
alternative IκB-independent pathway, direct phosphorylation
of NF-κB subunit p65 by IKK also modulates NF-κB tran-
scription activity [31]. In this study, kinsenoside inhibited
RANKL-induced NF-κB activation in RAW 264.7 cells by
inhibiting p-IκBα and p-p65. This indicates that kinsenoside
inhibited NF-κB translocation through both IκBα-dependent
and IκBα-independent pathways.
IKK is the major upstream kinase of IκBα in the NF-κB
signaling pathway. In this study, kinsenoside did not inhibit
IKK phosphorylation but suppressed the phosphorylation of
IκBα and p65. Therefore, this study also investigates the
effects of kinsenoside on IKK activity. Results show that
kinsenoside significantly inhibits RANKL induction of IKK
activity, suggesting that IKK is a critical target for kinseno-
side in inhibiting RANKL-induced osteoclastogenesis.
NFATc1 is likely a key regulator of RANKL-induced
osteoclast differentiation, fusion, and activation [10]. NF-
κB is important for the initial induction of NFATc1. The
binding of NF-κB to the NFATc1 promoter region induces
NFATc1 gene expression, allowing NFATc1 to autoamplify
its expression by binding to its own promoter. This, in turn,
leads to the robust induction of NFATc1 during RANKL-
induced osteoclast differentiation [32]. In this study, kinse-
noside significantly suppressed RANKL-induced NF-κB
translocation and NFATc1 nuclear transport.
NFATc1 promotes the expression of osteoclast-specific
genes such as TRAP, DC-STAMP, CAK, and MMP-9
[33–35]. In addition to histochemical marker for osteoclasts,
TRAP also regulates bone resorption by mediating the deg-
radation of endocytosed matrix products during transcytosis
in activated osteoclasts [36]. DC-STAMP, a putative seven-
transmembrane spanning protein, is essential for the cell–
cell fusion of osteoclasts [37]. Proteinases are necessary for
bone resorption. Delaisse et al. showed that CAK and MMP-
9 are key proteinases in the bone resorption processes [38].
The RT-PCR analysis in this study shows that kinsenoside
dose-dependently suppressed the mRNA expression of
TRAP, DC-STAMP, CAK, and MMP-9. Thus, kinsenoside,
which downregulates NF-κB and NFATc1 activities, caused
substantial inhibition of osteoclast differentiation, fusion,
and resorption mediated by RANKL.
This study shows that kinsenoside reduces osteoporosis
induced by OVX in mice. Second, kinsenoside has the poten-
tial to inhibit the formation of osteoclasts by inhibiting IKK
activity, which might influence the activation of NF-κB and
NFAcT1. Third, kinsenoside may suppress the bone resorp-
tion activity of mature osteoclasts by regulating the expression
of osteoclast fusion-related and resorption-related genes.
Many synthetic agents, such as bisphosphonates and
raloxifene, have been developed to treat osteoporosis. How-
ever, these drugs are associated with side effects such as
dyspepsia and breast cancer. Thus, scientists are pursuing
the development of natural products. This study investigates
the efficacy of kinsenoside in treating osteoporosis. Recent-
ly, we also found that A. formosanus contains prebiotic
polysaccharides that could reduce the osteopenia induced
by OVX in rats by increasing the concentration of cecal
short chain fatty acids (SCFA) [39]. Butyric acid, an SCFA,
can stimulate the formation of osteoblasts [40, 41]. There-
fore, it is possible that the extract of A. formosanus may
ameliorate bone loss caused by OVX by stimulating bone
formation and inhibiting bone resorption [19]. This study
proposes the possibility of using A. formosanus in the de-
velopment of therapeutic drugs for osteoporosis.
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